P

Inventor

HOFFMANN PATRICK

DE40 patents
⚠️ This page may combine multiple inventors who share the name “HOFFMANN PATRICK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

AMGEN RES MUNICH GMBH

32 patents
US9340621B2May 17, 2016

Binding molecules for BCMA and CD3

AMGEN RES MUNICH GMBH91 citations98
US10294300B2May 21, 2019

Antibody constructs for DLL3 and CD3

AMGEN RES MUNICH GMBH37 citations97
US9150664B2Oct 6, 2015

Binding molecules for BCMA and CD3

AMGEN RES MUNICH GMBH64 citations97
US10301391B2May 28, 2019

BCMA and CD3 bispecific T cell engaging antibody constructs

AMGEN RES MUNICH GMBH28 citations93
US9598500B2Mar 21, 2017

Binding molecules for BCMA and CD3

AMGEN RES MUNICH GMBH22 citations93
US10519241B2Dec 31, 2019

Antibody constructs for EGFRVIII and CD3

AMGEN RES MUNICH GMBH16 citations92
US9688760B2Jun 27, 2017

Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains

AMGEN RES MUNICH GMBH17 citations90
US11591396B2Feb 28, 2023

Antibody constructs for DLL3 and CD3

AMGEN RES MUNICH GMBH5 citations85
US10752694B2Aug 25, 2020

Binding molecules for BCMA and CD3

AMGEN RES MUNICH GMBH11 citations85
US10766969B2Sep 8, 2020

Binding molecules for BCMA and CD3

AMGEN RES MUNICH GMBH8 citations83
US10683351B2Jun 16, 2020

Antibody constructs for DLL3 and CD3

AMGEN RES MUNICH GMBH4 citations83
US10781264B2Sep 22, 2020

PSMA and CD3 bispecific T cell engaging antibody constructs

AMGEN RES MUNICH GMBH8 citations82
US10059766B2Aug 28, 2018

Antibody constructs for CDH19 and CD3

AMGEN RES MUNICH GMBH9 citations82
US11661462B2May 30, 2023

Optimized cross-species specific bispecific single chain antibody contructs

AMGEN RES MUNICH GMBH4 citations73
US11434302B2Sep 6, 2022

Bispecific T cell engaging antibody constructs

AMGEN RES MUNICH GMBH7 citations73
US11472886B2Oct 18, 2022

Cross-species-specific PSMAxCD3 bispecific single chain antibody

AMGEN RES MUNICH GMBH3 citations71
US11352433B2Jun 7, 2022

BCMA and CD3 bispecific T cell engaging antibody constructs

AMGEN RES MUNICH GMBH2 citations71
US11155629B2Oct 26, 2021

Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3

AMGEN RES MUNICH GMBH2 citations71
US11084876B2Aug 10, 2021

Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains

AMGEN RES MUNICH GMBH4 citations71
US9486475B2Nov 8, 2016

PPS for the prevention of potential adverse effects caused by CD3 specific binding domains

AMGEN RES MUNICH GMBH4 citations71
US11447567B2Sep 20, 2022

Antibody constructs for FLT3 and CD3

AMGEN RES MUNICH GMBH4 citations69
US10851170B2Dec 1, 2020

Antibody constructs for CD70 and CD3

AMGEN RES MUNICH GMBH3 citations67
US12435139B2Oct 7, 2025

Antibody constructs for DLL3 and CD3

AMGEN RES MUNICH GMBH0 citations62
US12304952B2May 20, 2025

Antibody constructs for DLL3 and CD3

AMGEN RES MUNICH GMBH0 citations62
US11987633B2May 21, 2024

Cross-species-specific single domain bispecific single chain antibody

AMGEN RES MUNICH GMBH1 citations62
US12428491B2Sep 30, 2025

PSMA and CD3 bispecific T cell engaging antibody constructs

AMGEN RES MUNICH GMBH0 citations61
US12152078B2Nov 26, 2024

Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3

AMGEN RES MUNICH GMBH0 citations61
US11498964B2Nov 15, 2022

Antibody constructs for CDH19 and CD3

AMGEN RES MUNICH GMBH1 citations61
US12281172B2Apr 22, 2025

Cross-species-specific PSMAxCD3 bispecific single chain antibody

AMGEN RES MUNICH GMBH0 citations60
US11884720B2Jan 30, 2024

Antibody constructs for MSLN and CD3

AMGEN RES MUNICH GMBH1 citations60
US11926666B2Mar 12, 2024

Bispecific antibody constructs for CDH3 and CD3

AMGEN RES MUNICH GMBH0 citations57
US11028171B2Jun 8, 2021

Bispecific antibody constructs for CDH3 and CD3

AMGEN RES MUNICH GMBH1 citations57

AMGEN INC

5 patents

KUFER PETER

1 patent

HOFFMANN PATRICK

1 patent

ROETELZEICHNUNG HOLDING A G

1 patent